Giovanni Gaudino

University of Hawaiʻi at Mānoa — United States

Medicine · Health Sciences

53h-index13.2kcitations202works5.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Occupational and environmental lung diseases(97), Cancer Research and Treatments(29), Liver physiology and pathology(20), Medical Imaging and Pathology Studies(20), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis(16)

Publications200 total

A Response to the Letter to the Editor: Refining Risk and Redefining Stage: Hidden Implications of BAP1-Mutant Mesothelioma Shiuan-Chih Chen, MD, PhD; Yuan-Ti Lee, MD, PhD
Journal of Thoracic Oncology·2025
Clinical and Pathologic Phenotyping of Mesotheliomas Developing in Carriers of Germline BAP1 Mutations
Journal of Thoracic Oncology·2025· 11 citedOpen Access
Germline <i>BARD1</i> variants predispose to mesothelioma by impairing DNA repair and calcium signaling
Proceedings of the National Academy of Sciences·2024· 10 citedOpen Access
Mechanisms of Asbestos Carcinogenesis
2024· 1 cited
HMGB1 released by mesothelial cells drives the development of asbestos-induced mesothelioma
Proceedings of the National Academy of Sciences·2023· 23 citedOpen Access
Abstract 5919: The significant role of HMGB1 in mesothelial cells in contributing to the mesothelioma development induced by asbestos
Cancer Research·2023
Supplementary Figure 4 from CSPG4 as a Target of Antibody-Based Immunotherapy for Malignant Mesothelioma
2023Open Access
Data from CSPG4 as a Target of Antibody-Based Immunotherapy for Malignant Mesothelioma
2023Open Access
Data from CSPG4 as a Target of Antibody-Based Immunotherapy for Malignant Mesothelioma
2023Open Access
Supplementary Figure 4 from CSPG4 as a Target of Antibody-Based Immunotherapy for Malignant Mesothelioma
2023Open Access
Supplementary Figure 2 from CSPG4 as a Target of Antibody-Based Immunotherapy for Malignant Mesothelioma
2023Open Access
Supplementary Figure Legend from CSPG4 as a Target of Antibody-Based Immunotherapy for Malignant Mesothelioma
2023Open Access
Supplementary Figure 3 from CSPG4 as a Target of Antibody-Based Immunotherapy for Malignant Mesothelioma
2023Open Access
Supplementary Figure 3 from CSPG4 as a Target of Antibody-Based Immunotherapy for Malignant Mesothelioma
2023Open Access
Supplementary Figure 1 from CSPG4 as a Target of Antibody-Based Immunotherapy for Malignant Mesothelioma
2023Open Access
Supplementary Figure 2 from CSPG4 as a Target of Antibody-Based Immunotherapy for Malignant Mesothelioma
2023Open Access
Supplementary Figure 6 from CSPG4 as a Target of Antibody-Based Immunotherapy for Malignant Mesothelioma
2023Open Access
Supplementary Figure 5 from CSPG4 as a Target of Antibody-Based Immunotherapy for Malignant Mesothelioma
2023Open Access
Supplementary Figure 6 from CSPG4 as a Target of Antibody-Based Immunotherapy for Malignant Mesothelioma
2023Open Access
Supplementary Figure 5 from CSPG4 as a Target of Antibody-Based Immunotherapy for Malignant Mesothelioma
2023Open Access
page 1 of 10Next →

Frequent Co-authors

Haining Yang(21), Harvey I. Pass(20), Michele Carbone(20), Paolo M. Comoglio(12), Sandra Pastorino(9), Andrea Napolitano(9), Mika Tanji(8), Luciano Mutti(8), Amy Powers(7), Angela Bononi(7), Masaki Nasu(6), Massimo Santoro(6), Luigi Naldini(5), Ian Pagano(5), Sandro Jube(5), Thomas Krausz(4), Carlotta Giorgi(4), Paolo Pinton(4), Mitsuru Emi(4), Francine Baumann(4)